Loading...
Market
How will Pfizer's stock price change within a month after FDA approval of Sasanlimab with BCG?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Stock market data and financial reports
Story
Pfizer's Phase 3 Study Shows Sasanlimab with BCG Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer
Jan 10, 2025, 11:52 AM
Pfizer has announced positive topline results from its Phase 3 study indicating that Sasanlimab, when combined with Bacillus Calmette-Guérin (BCG), improves event-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint as assessed by investigators. Pfizer also reported that the safety profile of Sasanlimab was consistent with previous findings, suggesting a favorable outcome for this treatment approach in a challenging patient population.
View original story
Similar markets
Increase by more than 10% • 25%
No significant change or decrease • 25%
Increase by less than 5% • 25%
Increase by 5-10% • 25%
Outperforms biotech index • 25%
No significant change • 25%
Underperforms biotech index • 25%
Performs in line with biotech index • 25%
Increase 0-20% • 25%
No change • 25%
Decrease • 25%
Increase over 20% • 25%
Increase by 10% or more • 25%
Decrease by 10% or more • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease • 25%
No significant change • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by over 10% • 25%
Increase by over 10% • 25%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Other • 25%
Decrease over 10% • 25%
Increase over 10% • 25%
No significant change • 25%
No • 50%
Yes • 50%
